Original Article

Journal of Bone and Mineral Metabolism

, Volume 28, Issue 2, pp 157-164

First online:

Antitumor necrotic factor agent promotes BMP-2-induced ectopic bone formation

  • Yoshitaka EguchiAffiliated withDepartment of Orthopaedic Surgery, Osaka City University Graduate School of Medicine
  • , Shigeyuki WakitaniAffiliated withDepartment of Orthopaedic Surgery, Osaka City University Graduate School of Medicine Email author 
  • , Yuuki ImaiAffiliated withDepartment of Orthopaedic Surgery, Osaka City University Graduate School of Medicine
  • , Yoshifumi NakaAffiliated withDepartment of Orthopaedic Surgery, Osaka City University Graduate School of Medicine
  • , Yuusuke HashimotoAffiliated withDepartment of Orthopaedic Surgery, Osaka City University Graduate School of Medicine
  • , Hiroaki NakamuraAffiliated withDepartment of Orthopaedic Surgery, Osaka City University Graduate School of Medicine
  • , Kunio TakaokaAffiliated withDepartment of Orthopaedic Surgery, Osaka City University Graduate School of Medicine

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Etanercept (ETN), which is a recombinant human soluble tumor necrosis factor (TNF) receptor that inhibits TNF activity, is effective in the treatment of rheumatoid arthritis. We investigated the effect of ETN on recombinant human bone morphogenetic protein-2 (rhBMP-2)-induced ectopic bone formation in vivo. A block copolymer composed of poly-d,l-lactic acid with random insertion of p-dioxanone and polyethylene glycol (PLA–DX–PEG polymer) was used as the delivery system. Polymer discs (6 mm, 30 mg) containing 5 μg rhBMP-2 were implanted into the left dorsal muscle pouch of mice (n = 50). In the systemic administration groups (n = 5 per group), ETN was subcutaneously injected (25 mg/human = 12.5 μg/mouse) twice per week in a dose-dependent manner (placebo, 12.5 × 10−3, 12.5 × 10−1, 12.5, 125 μg), whereas a single dose of ETN (placebo, 12.5 × 10−3, 12.5 × 10−1, 12.5, 125 μg) was embedded in each rhBMP-2 polymer disc in the local administration groups (n = 5 per group). Three weeks after implantation, the mice were killed and the implants were analyzed. Implants in the optimally dosed groups had increased radiodensity, which was consistent with a significant increase in bone mineral content of the ossicles. Bone histomorphology revealed a significant increase in bone volume/total volume, number of osteoblasts, osteoblast surface/bone surface, and a significant decrease in the number of osteoclasts, osteoclast surface/bone surface in the optimal dosed systemic and locally administered groups. These data suggest that the optimal dose of ETN, administered either systemically or locally, enhanced the bone-inducing capacity of BMP with no apparent adverse systemic effects.

Keywords

Tumor necrosis factor-α Bone morphogenetic protein-2 Etanercept Osteoclast Osteoblast